CapsoVision (NASDAQ:CV) Shares Gap Down – What’s Next?

by · The Markets Daily

CapsoVision, Inc. (NASDAQ:CV – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $11.80, but opened at $10.78. CapsoVision shares last traded at $12.38, with a volume of 1,797,496 shares trading hands.

Analysts Set New Price Targets

A number of research firms have issued reports on CV. Weiss Ratings reiterated a “sell (e)” rating on shares of CapsoVision in a research report on Monday. Roth Capital set a $7.00 target price on CapsoVision in a research report on Tuesday, November 4th. Benchmark restated a “speculative buy” rating on shares of CapsoVision in a report on Friday, November 14th. Finally, Zacks Research upgraded shares of CapsoVision to a “hold” rating in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.00.

View Our Latest Stock Report on CV

CapsoVision Stock Performance

The firm’s 50-day moving average price is $5.71.

CapsoVision (NASDAQ:CV – Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $3.54 million for the quarter.

Institutional Investors Weigh In On CapsoVision

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund bought a new stake in CapsoVision, Inc. (NASDAQ:CV – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,114 shares of the company’s stock, valued at approximately $34,000.

CapsoVision Company Profile

(Get Free Report)

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.

Read More